Abbott inks companion diagnostic deals with a pair of biotechs


Abbott struck companion diagnostic deals with two biotech companies to use its PCR testing to identify mutations in leukemia patients that would make them a good fit for therapy.  

The company will work with Celgene ($CELG) and Agios Pharmaceuticals ($AGIO) to develop tests that run on its m2000 RealTime System. The tool pinpoints isocitrate dehydrogenase (IDH) mutations in individuals with acute myeloid leukemia (AML) to see if they’d respond to the companies’ new treatments for the disease.

Celgene and Agios have already used Abbott’s system in clinical trials, including a Phase III study that compares Celgene’s new treatment for the disease with conventional therapy in older patients with an IDH2 mutation and relapsed or refractory AML, the companies said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

IDH1 and IDH2 mutations crop up in 20% of AML patients, the company said, so having a tool that could identify them sooner could better direct treatment.

“AML is a complex and heterogeneous disease, making it difficult to treat,” Han Myint, vice president of Celgene’s global medical affairs, myeloid business, said in a statement. “Molecular profiling is important to identify genomic mutations which may have prognostic and potential treatment implications for patients with AML.”

The partnerships come at a critical moment. Personalized medicine is all the rage in the diagnostics industry, and more companies are pairing up with biotech or pharma partners to develop targeted companion diagnostic tests.

Abbott is far from the only one jumping on the bandwagon. Last week, Exosome Diagnostics said it would partner with biotech heavyweight Amgen ($AMGN) to create a liquid biopsy test for drug development.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.